ADAR

PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer
PACT suppresses PKR activation in TNBC
Addison Young, Isabelle Juhler, Jackson Pierce, Holly Bohlin, Haley A. Harper, David Onishile, Renee Chua, Madison Liu, Estelle Gardner, Bennett D. Elzey, Kyle A. Cottrell
PDF DOI
PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer
Suppression of double-stranded RNA sensing in cancer; molecular mechanisms and therapeutic potential
Review of dsRNA sensing in cancer.
Addison Young, Holly Bohlin, Jackson Pierce, Kyle A. Cottrell
PDF DOI
Suppression of double-stranded RNA sensing in cancer; molecular mechanisms and therapeutic potential
Activation of PKR by a short-hairpin RNA
A short-hairpin RNA targeting DDX54 causes off-target direct activation of PKR
Kyle A. Cottrell, Sua Ryu, Helen Donelick, Hung Mai, Addison Young, Jackson Pierce, Brenda L. Bass, Jason D. Weber
PDF DOI
Activation of PKR by a short-hairpin RNA
Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells
ADAR1 and DHX9 redundantly suppress dsRNA sensing in breast cancer
Kyle A. Cottrell, Sua Ryu, Jackson Pierce, Luisangely Soto-Torres, Holly Bohlin, Angela M. Schab, Jason D. Weber
PDF DOI
Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells
The competitive landscape of the dsRNA world
Review of dsRNAs, dsRNA binding proteins, and the role of competition in suppression of dsRNA sensing
Kyle A. Cottrell, Ryan Andrews, Brenda Bass
PDF DOI
The competitive landscape of the dsRNA world
8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR
The small molecule adenosine analogues, 8-azaadenosine and 8-chloroadenosine, are not selective inhibitors of ADAR
Kyle A. Cottrell, Luisangely Soto-Torres, Michael G. Dizon, Jason D. Weber
PDF DOI
8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR
Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer
ADAR is required for the growth and proliferation of a subset of triple-negative breast cancer cell lines
Che-Pei Kung, Kyle A. Cottrell, Sua Ryu, Emily R. Bramel, Raleigh D. Kladney, Emily A. Bao, Eric C. Freeman, Thwisha Sabloak, Jason D. Weber
PDF DOI
Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer